miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma

[1]  Jiandong Shi,et al.  Deep RNA Sequencing Reveals a Repertoire of Human Fibroblast Circular RNAs Associated with Cellular Responses to Herpes Simplex Virus 1 Infection , 2018, Cellular Physiology and Biochemistry.

[2]  R. Luan,et al.  MicroRNA-574 enhances doxorubicin resistance through down-regulating SMAD4 in breast cancer cells. , 2018, European review for medical and pharmacological sciences.

[3]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[4]  Carol J Bult,et al.  The Mouse Tumor Biology Database: A Comprehensive Resource for Mouse Models of Human Cancer. , 2017, Cancer research.

[5]  D. Sabatini,et al.  NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis , 2017, Nature.

[6]  Lili Han,et al.  Maternally Expressed Gene 3 (MEG3) Enhances PC12 Cell Hypoxia Injury by Targeting MiR-147 , 2017, Cellular Physiology and Biochemistry.

[7]  Stuart L. Schreiber,et al.  Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition , 2017, Nature.

[8]  Sydney M. Shaffer,et al.  Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance , 2017, Nature.

[9]  F. Slack,et al.  Targeting noncoding RNAs in disease , 2017, The Journal of clinical investigation.

[10]  F. Slack,et al.  MicroRNA therapeutics: towards a new era for the management of cancer and other diseases , 2017, Nature Reviews Drug Discovery.

[11]  M. Boutros,et al.  Wnt signaling in cancer , 2016, Oncogene.

[12]  C. James,et al.  Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation. , 2015, Cell reports.

[13]  Jordan Anaya,et al.  OncoRank: A pan-cancer method of combining survival correlations and its application to mRNAs, miRNAs, and lncRNAs , 2016 .

[14]  R. Xavier,et al.  Succinate Dehydrogenase Supports Metabolic Repurposing of Mitochondria to Drive Inflammatory Macrophages , 2016, Cell.

[15]  Jianguo Xia,et al.  Using MetaboAnalyst 3.0 for Comprehensive Metabolomics Data Analysis , 2016, Current protocols in bioinformatics.

[16]  J. Cheng,et al.  pVHL suppresses kinase activity of Akt in a proline-hydroxylation–dependent manner , 2016, Science.

[17]  F. Slack,et al.  ADARs Edit MicroRNAs to Promote Leukemic Stem Cell Activity. , 2016, Cell stem cell.

[18]  M. Haigis,et al.  Mitochondria and Cancer , 2016, Cell.

[19]  B. Lim,et al.  Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression , 2016, Nature Communications.

[20]  David S. Wishart,et al.  Heatmapper: web-enabled heat mapping for all , 2016, Nucleic Acids Res..

[21]  Navdeep S. Chandel,et al.  Fundamentals of cancer metabolism , 2016, Science Advances.

[22]  K. Flaherty,et al.  Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy , 2016, Cancer cell.

[23]  Bruce A. Posner,et al.  Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells , 2016, Nature Communications.

[24]  B. Faubert,et al.  Metabolic Heterogeneity in Human Lung Tumors , 2016, Cell.

[25]  G. Getz,et al.  Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition , 2016, Nature Medicine.

[26]  A. Califano,et al.  An ID2-dependent mechanism for VHL inactivation in cancer , 2015, Nature.

[27]  Hao Liu,et al.  MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells. , 2015, International journal of oncology.

[28]  Eyal Gottlieb,et al.  Oncometabolites: tailoring our genes , 2015, The FEBS journal.

[29]  Aleksandra Markovets,et al.  Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M , 2015, Nature Medicine.

[30]  Gail H Deutsch,et al.  In vitro generation of human pluripotent stem cell derived lung organoids , 2015, eLife.

[31]  Thomas D. Wu,et al.  A comprehensive transcriptional portrait of human cancer cell lines , 2014, Nature Biotechnology.

[32]  G. Semenza,et al.  Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells , 2014, Proceedings of the National Academy of Sciences.

[33]  P. Schumacker,et al.  Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel? , 2014, Nature Reviews Cancer.

[34]  F. Ishikawa,et al.  Human cancer growth and therapy in immunodeficient mouse models. , 2014, Cold Spring Harbor protocols.

[35]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[36]  T. Tan,et al.  FZD7 drives in vitro aggressiveness in Stem-A subtype of ovarian cancer via regulation of non-canonical Wnt/PCP pathway , 2014, Cell Death and Disease.

[37]  B. Lim,et al.  Glycine decarboxylase is an unusual amino acid decarboxylase involved in tumorigenesis. , 2014, Biochemistry.

[38]  T. Yeatman,et al.  MicroRNA-147 Induces a Mesenchymal-To-Epithelial Transition (MET) and Reverses EGFR Inhibitor Resistance , 2014, PloS one.

[39]  E. Mercken,et al.  Declining NAD+ Induces a Pseudohypoxic State Disrupting Nuclear-Mitochondrial Communication during Aging , 2013, Cell.

[40]  J. Engelman,et al.  Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer , 2013, Science Signaling.

[41]  David G Hendrickson,et al.  Differential analysis of gene regulation at transcript resolution with RNA-seq , 2012, Nature Biotechnology.

[42]  W. Kim,et al.  Clinical investigation of EGFR mutation detection by pyrosequencing in lung cancer patients. , 2013, Oncology letters.

[43]  Jane Fridlyand,et al.  Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors , 2012, Nature.

[44]  V. Mootha,et al.  Metabolite Profiling Identifies a Key Role for Glycine in Rapid Cancer Cell Proliferation , 2012, Science.

[45]  J. Asara,et al.  A positive/negative ion–switching, targeted mass spectrometry–based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue , 2012, Nature Protocols.

[46]  P. Ward,et al.  Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. , 2012, Cancer cell.

[47]  P. Robson,et al.  Glycine Decarboxylase Activity Drives Non-Small Cell Lung Cancer Tumor-Initiating Cells and Tumorigenesis , 2012, Cell.

[48]  Brian Keith,et al.  HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression , 2011, Nature Reviews Cancer.

[49]  G. Shadel,et al.  Revisiting the TCA cycle: signaling to tumor formation. , 2011, Trends in molecular medicine.

[50]  E. Liu,et al.  Pyrosequencing enhancement for better detection limit and sequencing homopolymers. , 2010, Biochemical and biophysical research communications.

[51]  Kwok-Kin Wong,et al.  Primary tumor genotype is an important determinant in identification of lung cancer propagating cells. , 2010, Cell stem cell.

[52]  Junjie Chen,et al.  Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. , 2010, Molecular cell.

[53]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[54]  E. Barillot,et al.  miR-181a and miR-630 regulate cisplatin-induced cancer cell death. , 2010, Cancer research.

[55]  M. Robinson,et al.  A scaling normalization method for differential expression analysis of RNA-seq data , 2010, Genome Biology.

[56]  G. Smyth,et al.  ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. , 2009, Journal of immunological methods.

[57]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[58]  Cole Trapnell,et al.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.

[59]  W. Kaelin.  The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer , 2008, Nature Reviews Cancer.

[60]  W. Krek,et al.  pVHL: A Multipurpose Adaptor Protein , 2008, Science Signaling.

[61]  A. Tanswell,et al.  A Critical Role for Fibroblast Growth Factor-7 during Early Alveolar Formation in the Neonatal Rat , 2008, Pediatric Research.

[62]  S. Nishikawa,et al.  A ROCK inhibitor permits survival of dissociated human embryonic stem cells , 2007, Nature Biotechnology.

[63]  E. Gottlieb,et al.  Cell-Permeating α-Ketoglutarate Derivatives Alleviate Pseudohypoxia in Succinate Dehydrogenase-Deficient Cells , 2007, Molecular and Cellular Biology.

[64]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[65]  P. M. Nissom,et al.  A novel normalization method for effective removal of systematic variation in microarray data , 2006, Nucleic acids research.

[66]  J. Aragonés,et al.  Activation of HIF-prolyl Hydroxylases by R59949, an Inhibitor of the Diacylglycerol Kinase* , 2005, Journal of Biological Chemistry.

[67]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[68]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[69]  H. Varmus,et al.  KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.

[70]  David G. Watson,et al.  Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.

[71]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[72]  W. Kaelin,et al.  Molecular basis of the VHL hereditary cancer syndrome , 2002, Nature Reviews Cancer.

[73]  W. Hahn,et al.  Immortalization and transformation of primary human airway epithelial cells by gene transfer , 2002, Oncogene.

[74]  M. Ivan,et al.  HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.

[75]  Michael I. Wilson,et al.  Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.

[76]  Nobuyuki Itoh,et al.  Fgf10 is essential for limb and lung formation , 1999, Nature Genetics.

[77]  C. Betsholtz,et al.  PDGF-A Signaling Is a Critical Event in Lung Alveolar Myofibroblast Development and Alveogenesis , 1996, Cell.

[78]  C. Veeger,et al.  STUDIES ON SUCCINATE DEHYDROGENASE. I. SPECTRAL PROPERTIES OF THE PURIFIED ENZYME AND FORMATION OF ENZYME-COMPETITIVE INHIBITOR COMPLEXES. , 1964, Biochimica et biophysica acta.